Market Reports

Tailor-made molecules for the drugs of tomorrow

Getting a drug to market is no easy feat, especially with tight regulations to comply with and the plethora of products that are already available. This is why a service that streamlines the discovery process and leads to improved outcomes during clinical trials for drug candidates is likely to be very desirable

PCI expands analytical laboratories at Tredegar site

Pharmaceutical outsourcing services provider PCI announces laboratory expansion at contained manufacturing centre

Standing strong

As regulatory pressure keeps rising, affecting every aspect of the drug manufacturing process, quality is an ongoing quest for pharma companies. Kevin Robinson spoke to Christina Rettig, Head of Communications at SCHOTT AG to find out more

Addressing glass particulates in injectable drug formulations

Glass particles are a frequent contaminant risk when producing injectable drugs on high speed filling lines. Glassmaker Corning has studied the root causes and engineered a new glass product for use on existing equipment that significantly reduces that risk

Serialisation: one year and counting

The Falsified Medicines Directive (FMD) introduces pan-European measures to prevent counterfeit medicines from entering the supply chain

A modern take on sterility assurance

Pharmaceutical manufacturers are increasingly looking for strategies to address containment risks. Christian Dunne of ChargePoint Technology sheds light on the benefit of split butterfly valve technology (SBV) in the aseptic processing of sterile active APIs and the final product

A look back at 2017 healthcare transactions

Last year, 2017, saw 2011 deals complete, with Q2 showing the strongest performance with 29.4%, followed by Q1 with 27.6%, Q3 with 24.1% and Q4 with 18.9%

Weathering the Brexit storm

The effective use of technology could facilitate regulatory compliance for pharmaceutical companies

Performance validation: HPAPI containment testing in a risk-based era

Taking a more automated approach to validation testing paves the way to capturing more repeatable and reliable data, thereby improving levels of containment performance

Gene transfer therapy approved for the treatment of ALL: part I

In August 2017, Novartis received FDA approval for its chimeric antigen receptor T (CAR-T) cell therapy, Kymriah, for the treatment of children and young adults with B-cell acute lymphoblastic leukaemia (ALL)

The race to be first: drug delivery systems for biosimilars

For biosimilar manufacturers, the market potential is significant, especially for those that are first to market

Improving cold chain performance and reliability

The need to mitigate risks within global pharmaceutical supply chain logistics is driving innovation within the temperature-controlled packaging sector

Trending Articles

  1. UK pharma shifts as Merck and AstraZeneca scale back: can CDMOs fill the gap? Recent major site withdrawals and investment pauses have raised concerns about the UK’s industrial strength. But CDMOs say agility, innovation and technical expertise could redefine how and where drugs are made
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Performance validation: HPAPI containment testing in a risk-based era Taking a more automated approach to validation testing paves the way to capturing more repeatable and reliable data, thereby improving levels of containment performance
  3. QInscribe unveils AI-powered medical writing to revolutionise regulatory submissions New medical writing service provider QInscribe reduces the time to generate a draft clinical study report (CSR) by 90% with a generative AI solution
  4. Peak identification by LC/MS: Automation versus analyst High pressure liquid chromatography/mass spectrometry (LC/MS) is an important technique that facilitates the correct and accurate identification of impurities in pharmaceutical products and intermediates
  5. Recombinant versus synthetic peptide synthesis: the perks and drawbacks Since the introduction of novel peptide drugs into the market, the demand for polypeptide manufacturing has significantly increased, reports Dr Philipp Markolin